PP
TCRT icon

PFS Partners’s Alaunos Therapeutics TCRT Stock Holding History

PFS Partners’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7
Closed -$47 – 461
2024
Q2 		$47 Hold
7
– – ﹤0.01% 435
2024
Q1 		$120 Hold
7
– – ﹤0.01% 456
2023
Q4 		$71 Hold
7
– – ﹤0.01% 459
2023
Q3 		$132 Hold
7
– – ﹤0.01% 456
2023
Q2 		$510 Hold
7
– – ﹤0.01% 458
2023
Q1 		$630 Hold
7
– – ﹤0.01% 364
2022
Q4 		$650 Hold
7
– – ﹤0.01% 354
2022
Q3 		$1.72K Hold
7
– – ﹤0.01% 317
2022
Q2 		$1.24K Hold
7
– – ﹤0.01% 328
2022
Q1 		$653 Hold
7
– – ﹤0.01% 332
2021
Q4 		$1.09K Buy
+7
New +$1.54K ﹤0.01% 322

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
SWM
Sugarloaf Wealth Management Duluth, Georgia $529M AUM 14.14% 1-Year Est. Return

PFS Partners's TCRT Position: Q3 2024 in Review

PFS Partners sold out of Alaunos Therapeutics (TCRT) in Q3 2024, closing a stake of 7 shares — an estimated $47 sold.

PFS Partners first reported a position in TCRT in Q4 2021 and held it in 11 quarters. The position peaked at $1.72K in Q3 2022. 29 funds tracked by Wall St. Rank hold TCRT as of Q3 2024.

  • PFS Partners reported no remaining Alaunos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • PFS Partners sold 7 Alaunos Therapeutics shares in Q3 2024, an estimated $47.
  • PFS Partners first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 11 quarters.
  • PFS Partners's Alaunos Therapeutics position peaked at $1.72K in Q3 2022.
  • 29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2024.

Based on PFS Partners's 13F filing for Q3 2024, filed 1 Nov 2024.